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A study of adverse reaction algorithms in 
a drug surveillance program 
To improve agreement among observers, several investigators have recently proposed methods 
(algorithms) to standardize assessments of causality for presumed adverse drug reactions. We evaluated 
one such method in the context of an intensive pediatric drug surveillance program. Four observers rated 
50 randomly selected case reports drawn from the program, first using only general guidelines and then, 
several months later, using the strict criteria of the algorithm. Agreement among observers was poor in 
both study phases. The presence of selected characteristics of adverse events (e.g., major severity) did not 
improve agreement in either phase of the study. We conclude that routine use of such algorithms in drug 
surveillance programs is not likely to be of benefit. (CLIN PHARMACOL THER 38:183-187, 1985.) 
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Adverse drug reactions are a well recognized cause 
of morbidity, and considerable attention has been de- 
voted to quantifying the extent of this problem. In most 
cases, however, the determination that a given clinical 
event is in fact an adverse reaction to a drug has been 
based on the judgment of a clinical observer. These 
judgments are almost certainly influenced by both the 
observer's experience and particular areas of concern, 
and it is not surprising that low rates of agreement have 
been documented among different investigators who 
evaluated selected cases of suspected adverse reac- 
tions.''' In response to this problem, several researchers 
have proposed sets of objective criteria, or "algo- 
rithms," to be applied in a systematic manner to sus- 
pected drug reactions. These algorithms ask a series of 
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questions, in sequence, the answers to which yield a 
score intended to measure the probability that the given 
event was in fact an adverse drug reaction.47,11,12 The 
algorithms share certain features, and although the pre- 
cise form of a particular question may differ, there are 
certain criteria that prove to be crucial in concluding 
that a clinical event is an adverse drug reaction. These 
include timing of the event relative to drug exposure, 
whether the event represents a known reaction to the 
drug, the possible role of the patient's condition at the 
time, and the effects of drug withdrawal and, where 
appropriate, rechallenge. 
Such standardized approaches to judging adverse 
drug reactions are intended to produce greater consis- 
tency among evaluators, and enhanced consistency has 
been demonstrated when such algorithms were tested 
by their developers.3'11 However, their potential utility 
in drug surveillance systems has not been assessed. As 
part of an intensive pediatric drug surveillance program, 
we routinely review cases of suspected adverse drug 
reactions and assess the likelihood that they are due to 
drugs. In our program, these assessments have been 
made informally by one observer alone. To determine 
whether adverse reaction algorithms enhance the con- 
sistency and usefulness of these assessments, we stud- 
ied one such algorithm in the context of the Pediatric 
Drug Surveillance (PeDS) Program. 
METHODS 
The PeDS Program is an intensive drug surveillance 
program established at Children's Hospital in Boston 
to detect previously unsuspected adverse drug reactions, 
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quantify known reactions, and identify risk factors for 
their development. The methods have been described 
in detail.' In brief, nurse monitors are stationed on 
selected wards where they systematically collect data 
on patients admitted to these wards. Data are collected 
in three general areas: patient characteristics, drug ex- 
posures, and adverse events. Adverse events include 
any of a defined set of adverse occurrences (e.g., renal 
failure, convulsions, rash). Regardless of whether or 
not such an event is attributed to a drug by a ward 
observer, the nurse monitor fills out a report form that 
describes details of the event, date of onset, severity, 
treatment, duration, and outcome. In addition, reports 
for events believed to be drug induced include infor- 
mation on the identity of the suspected drug(s), dosage, 
and an internal assessment by the PeDS Program Di- 
rector of the likelihood that the event was caused by 
the implicated drug. The likelihood is rated as definite, 
probable, possible, or doubtful. 
For this investigation we selected a stratified random 
sample of 50 case reports from among the adverse 
events reported during the course of routine surveillance 
of patients. These included 39 "adverse reactions," 
stratified to include equal numbers of reactions of ma- 
jor, moderate, and minor severity, and 11 events not 
suspected to be drug induced. For phase I of the study, 
the 50 case reports were reviewed by three pediatric 
clinical pharmacologists (R. K., F. H. L., S. J. Y.) 
who were not directly involved with the PeDS Program 
and by the PeDS Program Director (A. A. M.), who 
routinely assesses adverse reaction reports in the Pro- 
gram. To mimic the way assessments are made within 
the PeDS Program, all reviewers were asked to make 
an informal judgment as to the probability that each 
case was an adverse reaction to a suspected drug and 
to rate each case as "definite," "probable," "possi- 
ble," "doubtful," or "insufficient information." These 
terms were deliberately left undefined; we relied on the 
intuitive understanding of each reviewer to replicate the 
manner in which these assessments have traditionally 
been made. The consultant reviewers were told only 
that we were evaluating our assessments of adverse 
reactions; at this time no mention was made of algo- 
rithms. 
Phase II of the study began 3 months after the com- 
pletion of the first set of reviews. Our consultants were 
again sent the same 50 case reports, but this time they 
were asked to assess them using the algorithm proposed 
by Naranjo et al." This algorithm was chosen because 
it incorporates the principal features of most others and 
was judged in our pilot study to be easier to learn and 
faster to use. This algorithm consists of a set of 10 
questions, each of which can be answered "yes," 
"no," or "do not know," and each of the 10 responses 
is assigned a score. Our reviewers were asked to answer 
each question; the scores were tallied and each case 
report was then categorized according to the established 
criteria as a "definite," "probable," "possible," or 
"doubtful" drug-induced event." 
In both phases I and II, differences between raters 
were assessed with the test for marginal homogeneity 
proposed by Mantel and Byar.8 This is a generalization 
of the Mantel-Haenszel test for matched samples. We 
used Cohen's' K to measure pairwise agreement be- 
tween all pairs of raters, and then used an approach 
suggested by Fleiss2 to measure agreement among more 
than two raters by taking the average of all pairwise K 
values. The statistic K is a measure of the extent of 
agreement beyond that expected by chance; it ranges 
in value from 1 to + 1. Values >0.75 are generally 
considered to represent "good" agreement, values be- 
tween 0.4 and 0.75 to represent "fair" agreement, and 
values <0.4 to represent "poor" agreement. We also 
measured agreement with the intraclass correlation co- 
efficient (p), a statistic that is essentially equivalent to 
a weighted K provided the weights have a particular 
form.' Unlike the unweighted K, the intraclass corre- 
lation coefficient gives partial weighting to partial 
agreement (e.g., ratings from two reviewers of "defi- 
nite" and "probable" receive more credit than ratings 
of "definite" and "doubtful") and would therefore be 
expected to give slightly higher values than unweighted 
K when used to measure agreement in ordered cate- 
gories. 
RESULTS 
Table I shows the distribution of ratings for each 
rater. Because "insufficient information" was used 
only five times, these ratings were reclassified as "pos- 
sible" for all analyses. The Mantel-Byar tests for mar- 
ginal homogeneity indicate that in both phases of the 
study there were substantial differences in the frequency 
distributions of ratings for each rater. Thus in the ag- 
gregate, some raters were considerably more likely to 
choose a "definite" or "doubtful" rating. For example, 
in phase I, rater 2 used "definite" only four times (2%), 
while rater 1 chose it 15 times (30%). This difference 
was somewhat less marked in phase II, but still statis- 
tically significant. 
In Table II, agreement in assignment of ratings to 
individual cases as measured by both the K statistic and 
the intraclass correlation coefficient is shown for all 
pairwise combinations of raters as well as for all four 
raters considered together. As expected, in all cases the 
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Table I. Distribution of assessments of 50 adverse events according to rater 
Table II. Agreement among raters of 50 adverse events 
intraclass correlation coefficient indicates a greater de- 
gree of agreement than K. In phase I, when assessments 
were made without specified guidelines, agreement was 
poor as measured by either statistic, except for one pair 
of raters for whom r indicates fairly good agreement 
(r = 0.74). Application of the algorithm to assess cau- 
sality in phase II of the study did not improve agree- 
ment. Although the overall K indicates slightly better 
agreement, r is quite similar for the phase I and phase 
II assessments, and pairwise comparisons show no trend 
in either direction. 
We stratified the events according to characteristics 
that might affect the level of agreement. Factors selected 
were severity of the event, whether the event was orig- 
inally reported as drug attributed, whether treatment 
was required, and whether blood levels of the suspected 
drug had been measured (Table III). In general, for a 
given event characteristic, measures of agreement did 
not vary substantially in either phase. For example, in 
phase I, events that were of major severity were no 
more likely to yield agreement among raters than were 
events of minor severity; this finding held for phase II 
as well. However, agreement was better in both phases 
among the 39 events originally attributed to drugs than 
among the 11 events that were not. 
When results from phase I were compared with those 
from phase II, there was little evidence that use of the 
algorithm improved agreement for most of the event 
characteristics studied, although phase II agreement 
measures were better for those case reports that included 
a blood level value of the suspected drug. However, in 
no category did use of the algorithm raise agreement 
to "good" levels. 
DISCUSSION 
For any individual adverse event it is rarely possible 
to know with absolute certainty whether the event is 
drug induced. As a first step in approaching truth, one 
would hope to achieve a consensus among experts. Such 
consensus is difficult to obtain when judgments are 
made intuitively and when unspecified criteria are used 
to make the determination of drug involvement." This 
problem led several investigators to develop methods 
of standardizing assessments, and reports have sug- 
gested that agreement is indeed improved when these 
methods are used. In particular, Naranjo et al." used 
a study design similar to ours and demonstrated a 
change in the intraclass correlation coefficient from 
0.49 ("fair") to 0.92 ("good"). 
Our study is the first to consider the utility of these 
algorithms in the assessment of adverse events routinely 
identified as part of an intensive drug surveillance pro- 
Rater Definite Probable Possible Doubtful Definite Probable Possible Doubtful 
1 15 10 16 9 0 24 25 
2 4 20 19 7 5 10 32 3 
3 13 12 11 14 1 17 31 1 
4 12 13 6 19 7 14 27 2 
Phase I Phase II 
Sets of raters 
1-2 0.12 0.40 0.14 0.30 
1-3 0.44 0.74 0.42 0.51 
1-4 0.22 0.38 0.31 0.50 
2-3 0.21 0.40 0.20 0.38 
2-4 0.10 0.28 0.24 0.58 
3-4 0.27 0.56 0.36 0.62 
All raters 0.24 0.51 0.30 0.48 
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Phase I Phase II 
X' (df = 9; marginal homogeneity) = 35.4 X2 (df = 9; marginal homogeneity) = 21.7 
(P <0.005). (P < 0.01). 
Table III. Agreement among raters according to selected characteristics of events 
gram. While levels of agreement before use of the al- 
gorithm were similar in both the study of Naranjo 
et al." (r = 0.49) and our own (r = 0.51), we were 
unable to demonstrate that application of the algorithm 
led to improved agreement among raters. 
We believe there are two factors that account for our 
discordant findings. First, our raters were pediatric clin- 
ical pharmacologists who were not experienced in the 
use of any of the proposed algorithms. This criterion 
for selection of the raters was intended to assure that 
their first "informal" assessments would not be influ- 
enced by their unconscious application of any stan- 
dardized set of criteria. If this explanation is correct, 
it suggests that simple application of these algorithms 
as they are published will not automatically lead to 
greater consensus. 
Second, our case reports differ from those used in 
other studies to test algorithms. While we used reports 
derived from our routine surveillance, Naranjo et al. 
used published case reports. Unlike reports from inten- 
sive surveillance programs, which are necessarily brief 
and often based on incomplete information, published 
reports are more complete-in fact, they must contain 
sufficient evidence of a cause and effect relationship to 
justify publication. Thus such reports are more likely 
to include information on many of the important com- 
ponents required by the Naranjo et al. (and other) al- 
gorithms. For example, blood levels of the suspected 
drug would almost certainly be included in published 
reports, but may only infrequently be available for sus- 
pected reactions observed by a surveillance program. 
It is interesting that in our study, the most marked 
improvement in agreement with the use of an algorithm 
occurred for those events for which blood levels were 
available. 
The role of adverse drug reaction algorithms in a 
drug surveillance program must be kept in perspective. 
These algorithms are not designed to identify previously 
unreported adverse drug reactions, and their inclusion 
in a drug surveillance program would not enhance the 
capacity to detect such previously unrecognized reac- 
tions. That objective is better met by the use of "event 
surveillance," in which attributions of causality are not 
relevant. 10 Because event surveillance applies to pop- 
ulations of subjects, it cannot provide useful assess- 
ments of causality for individual cases. Algorithms 
would seem to be an alternative approach to this prob- 
lem. However, our findings indicate that the use of an 
algorithm in an intensive drug surveillance program 
does not improve the uniformity (or validity) of adverse 
drug reaction assessments. 
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